药物制造商Azurity Pharmaceuticals完成对Covis Pharma的收购-动脉网

Azurity Pharmaceuticals Completes Acquisition of Covis Pharma

CISION 等信源发布 2025-03-14 20:15



可切换为仅中文







WOBURN, Mass.

马萨诸塞州伍伯恩

，

March 14, 2025

2025年3月14日

/PRNewswire/ --

Azurity Pharmaceuticals

阿祖里蒂制药公司

('Azurity') announced today the successful completion of its acquisition of Covis Group S.à r.l. ('Covis') from existing investors. With this acquisition, Covis is now a wholly-owned subsidiary of Azurity.

Azurity今天宣布成功完成了对Covis Group S.à r.l.（“Covis”）的收购。通过此次收购，Covis现已成为Azurity的全资子公司。

This strategic acquisition reinforces Azurity's leadership in branded pharmaceuticals, harnessing the complementary strengths of both companies across multiple complex dosage forms and therapeutic areas. By combining expertise and resources, Azurity strengthens its ability to deliver medicines to overlooked patients on a global scale..

这项战略性收购巩固了Azurity在品牌制药领域的领导地位，充分利用了两家公司在多种复杂剂型和治疗领域的互补优势。通过整合专业知识和资源，Azurity增强了其在全球范围内为被忽视的患者提供药物的能力。

Strategic Benefits of the Acquisition:

收购的战略利益：

Expanded Therapeutic Portfolio

扩展的治疗组合

– The integration of Covis' product portfolio and pipeline enhances Azurity's offerings across ten complex dosage forms and nine key therapeutic areas, including cardiovascular, respiratory, central nervous system, endocrinology, gastrointestinal, hematology, immunology, anti-infectives, and oncology..

– Covis的产品组合和研发管线的整合增强了Azurity在十种复杂剂型和九大关键治疗领域（包括心血管、呼吸系统、中枢神经系统、内分泌学、胃肠病学、血液学、免疫学、抗感染药和肿瘤学）的产品供应。

Global Footprint

全球足迹

– The acquisition strengthens Azurity's global footprint, expanding its commercial presence to over 50 countries and enabling greater patient accessibility to life-changing treatments. Azurity and its subsidiaries will employ more than 800 colleagues across

此次收购加强了Azurity的全球影响力，将其商业版图扩展至超过50个国家，并使患者更容易获得改变生命的治疗。Azurity及其子公司将在全球拥有超过800名员工。

North America

北美

，

Europe

欧洲

and Asia.

和亚洲。

Key Biopharma Partner of Choice –

首选的关键生物制药合作伙伴 –

The combined company is positioned to be a key partner for global life sciences companies looking to develop and commercialize their products, providing partners access to its deep development capabilities and global commercial infrastructure.

合并后的公司将成为全球生命科学公司开发和商业化其产品的重要合作伙伴，为其合作伙伴提供深入的研发能力和全球商业基础设施。

Accelerated Innovation

加速创新

– By combining expertise and resources, Azurity is positioned to advance innovative treatments furthering Azurity's mission to serve overlooked patients using a unique and accelerated development process – enabling scale and velocity.

通过结合专业知识和资源，Azurity 有能力进一步推进创新治疗方案，践行 Azurity 服务被忽视患者的使命，利用独特且加速的开发流程，实现规模和速度的提升。

Next-Gen Commercial Model –

下一代商业模型 –

The integrated company portfolio will benefit from Azurity's highly efficient and effective commercial model, combining data, analytics, and AI-driven digital capabilities to drive stakeholder engagement using an optimized omnichannel marketing approach.

整合后的公司产品组合将受益于Azurity高效且有效的商业模式，结合数据、分析和人工智能驱动的数字能力，通过优化的全渠道营销方法推动利益相关者的参与。

'We are excited to welcome Covis Pharma to Azurity,' said

“我们很高兴欢迎Covis Pharma加入Azurity，”

Ronald Scarboro

罗纳德·斯卡伯勒

, CEO of Azurity

Azurity首席执行官

. 'The efforts of colleagues at both companies, their devotion to overlooked patients, and our culture of execution have brought us together to build this unique, highly differentiated pharmaceutical company. I look forward to all that we will accomplish as we grow globally and embrace new opportunities, driven by our purpose.'.

“两家公司的同事们的努力、他们对被忽视患者的奉献精神，以及我们执行的文化让我们走到了一起，共同创建了这家独特且高度差异化的制药公司。随着我们在全球范围内的成长并拥抱新机遇，我期待着我们将实现的一切，这都源于我们的使命。”

'I am delighted that Azurity recognized the accomplishments and potential of Covis, and am thankful for the tireless efforts of Covis colleagues in support of patients that benefit from the company's products,' said

“我很高兴Azurity认可了Covis的成就和潜力，并对Covis同事们为受益于公司产品的患者所做出的不懈努力表示感谢，”他表示。

Rajiv De Silva

拉吉夫·德·席尔瓦

, Chairman of the Board of Covis

，Covis董事会主席

. 'I am confident that the two companies will be able to untap each other's highly complementary capabilities to accelerate development and commercialization of necessary medicines to underserved patients.'

“我坚信，两家公司将能够挖掘彼此高度互补的能力，加速为服务不足的患者开发和商业化必要的药物。”

'QHP Capital is proud to support Azurity in this acquisition, which aligns with our commitment to investing in life sciences and healthcare innovations,' said

QHP Capital 很荣幸能够在这次收购中支持 Azurity，这与我们投资生命科学和医疗保健创新的承诺是一致的，

Jeff Edwards

杰夫·爱德华兹

, Partner at QHP Capital, the majority owner of Azurity.

，QHP资本的合伙人，Azurity的大股东。

'It has been our privilege to support and enable Azurity from a small, limited product, US-only company at the start of our investment in 2018 to the global, large, diversified portfolio, high-growth company it is today. We are committed to further enabling Azurity for the significant growth its team is well positioned to execute.'.

“自从我们2018年投资以来，从一家小型、产品有限、仅限美国的公司，到如今成为一家全球性、大型、多元化的产品组合、高增长的企业，支持和推动Azurity的发展一直是我们的荣幸。我们致力于进一步助力Azurity实现其团队已做好充分准备执行的重大增长。”

Goldman Sachs served as financial advisor and Eversheds Sutherland and White & Case served as legal advisors to Azurity. Guggenheim Securities served as financial advisor to Covis and

高盛担任Azurity的财务顾问，Eversheds Sutherland和White & Case担任Azurity的法律顾问。Guggenheim Securities担任Covis的财务顾问，

Reed Smith

里德·史密斯律师事务所

and A&O Shearman served as legal advisors to Covis.

A&O谢尔曼担任了Covis的法律顾问。

About Azurity Pharmaceuticals:

关于Azurity制药公司：

Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity's global footprint is over 50 countries, with a diversified portfolio of 30+ marketed brands spanning ten dosage forms and nine key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement.

Azurity Pharmaceuticals 是一家私营公司，致力于为被忽视的患者提供创新、高质量的药物。Azurity 的全球业务遍及 50 多个国家，拥有 30 多个上市品牌，涵盖十种剂型和九大关键治疗领域。通过其下一代商业模式，Azurity 利用数据、分析和人工智能驱动的数字工具来扩大市场覆盖范围并加强利益相关者的参与。

For more information, visit .

欲了解更多信息，请访问。

www.azurity.com

。

About QHP Capital:

关于QHP资本：

QHP Capital is an investor in technology and services companies in the life sciences, medical technology, and healthcare sectors. QHP has built an investment platform to provide strategic capital and industry expertise in partnership with strong management teams. The investment team consists of seasoned investment and operational professionals with significant investment experience and deep life science, medical technology, and healthcare expertise.

QHP Capital 是生命科学、医疗技术和医疗保健领域的技术和服务公司的投资者。QHP打造了一个投资平台，与强大的管理团队合作提供战略资本和行业专业知识。投资团队由资深的投资和运营专业人士组成，拥有丰富的投资经验以及深厚的生命科学、医疗技术和医疗保健专业背景。

QHP benefits from an extensive network of industry experts that assist in identifying, analyzing, and growing QHP's portfolio companies. For more information, please visit .

QHP 拥有一个广泛的行业专家网络，这些专家协助识别、分析并促进 QHP 投资组合公司的成长。欲了解更多信息，请访问。

www.qhpcapital.com

。

Disclosure notice:

披露通知：

Azurity and QHP undertake no obligation to update or revise any forward-looking statements contained in this release as a result of new information, future events, or evolving circumstances.

Azurity和QHP不承担因新信息、未来事件或情况变化而更新或修改本发布中包含的任何前瞻性陈述的义务。

SOURCE Azurity Pharmaceuticals

来源：Azurity Pharmaceuticals

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers